The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin
Open Access
- 1 July 1998
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 9 (7) , 711-716
- https://doi.org/10.1023/a:1008216430806
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Endomyocardial Changes in Anthracycline-Treated Patients with and without IrradiationPublished by S. Karger AG ,2015
- Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.Journal of Clinical Oncology, 1998
- Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.Journal of Clinical Oncology, 1997
- Anthracycline-Induced CardiotoxicityAnnals of Internal Medicine, 1996
- Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposiʼs sarcomaAIDS, 1996
- Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacyEuropean Journal of Cancer and Clinical Oncology, 1989
- Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly ScheduleAnnals of Internal Medicine, 1983
- Clinical and morphologic cardiac findings after anthracycline chemotherapyThe American Journal of Cardiology, 1983
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Techniques for right and left ventricular endomyocardial biopsyThe American Journal of Cardiology, 1978